Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,176.1
26.9 (0.85%)

 

  • STI Straits Times Index
    3,176.1
    26.9 (0.85%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,484.6
    -15.7 (-1.05%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    26,569.9
    375.1 (1.43%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    3,461.2
    13.2 (0.38%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    27,603.6
    -38.3 (-0.14%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,147.0
    16.4 (0.27%)
    Index delayed 10 minutes

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 581.7M
  • Value: 504.1M
  • Rise: 166
  • Fall: 89
  • Unch: 505

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Sembcorp Marine0.123+0.001
Intl Cement0.027+0.001
China Star Food0.028+0.003
Golden Agri-Res0.240+0.005
GKE0.149+0.005
Jiutian Chemical0.085+0.002
Samko Timber0.031+0.002
Oceanus^0.036-
Rex Intl0.245+0.010
ThaiBev0.665+0.020

World Indices

World Indices
Name Last Change
Nasdaq 14,761.3 +80.2
HSI 26,573.4 +378.6
HSCEI 9,466.2 +145.8
Jakarta 6,148.0 +17.4
Nikkei 225 27,603.6 -38.3
SSE Comp 3,461.2 +13.2
Shanghai A 3,627.7 +13.9
Shanghai B 258.3 +0.8
KOSPI 3,271.4 +34.3

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

Hyphens Pharma HYPHENS PHARMA INTL LIMITED
Quotes 10 Minutes Delayed. Updated at 04 Aug 2021 11:08
Last (SGD): 0.310 Change: +0.005 High: 0.315 Remarks: -
Change (%): +1.64 Low: 0.310
Open 0.310 Yesterday's Close 0.305
Buy Price 0.305 Sell Price 0.315
Buy Volume ('000) 71.7 Sell Volume ('000) 42.9
Cumulative Volume ('000) 21.4 Cumulative Value 6,639
Click to show Stock Prices chart

Key Statistics

EPS (SGD) a 0.02051 Trailing EPS (SGD) e 0.02051 NAV (SGD) b 0.1570
PE a 15.115 Trailing PE f 15.112 Price / NAV b 1.9745
Dividend (SGD) d 0.006200 Cash In Hand (SGD) g 0.0916 Issued & Paid-up Shares c 300,430,000
Dividend Yield (%) d 2.000 Price / Cash In Hand g 3.384 Treasury Shares h -
Beta - 75 Daysi 0.998 R-Squared - 75 Days(%)i 8.86 Market Cap (M) 93.133
Beta - 500 Daysi 0.440 R-Squared - 500 Days (%)i 1.21 Enterprise Value (M) 70.581
Piotroski F Score 4 Exchange Code 1J5 Par Value ( SGD ) n.a.
52 Weeks Volatility (%) 39.0031 6-Month VWAP 0.328 Free Float (%) 45.9
Under CPF Investment Scheme (CPFIS) No
Sector & Industry Wholesale and Retail Trade - Pharmaceuticals: Major
Category Classification Medical & Biotechnology
Index Components FTSE ST Catalist Index
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 08 Mar 2021.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand.
  9. Beta and R-Squared are calculated in relation to the market index (STI or KLCI) using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference Hyphens Pharma SGX 93.133 15.115 15.112 1.9745 2.000
Industry Medical & Biotechnology SGX 975.228 20.399 19.354 1.3967 1.984
Pharmaceuticals: Major SGX 87.656 2431.015 115.115 3.5056 0.708
Index FTSE ST Catalist Index SGX 65.430 108.911 50.894 1.5508 1.642
Local Peer IX Biopharma SGX 171.619 - - 6.5527 -
Local Peer Pharmesis Intl SGX 3.450 - - 0.3028 -
Global Peer JOHNSON & JOHNSON NYSE 459,078.187 31.200 25.839 6.5979 2.282
Global Peer PFIZER INC NYSE 255,702.479 26.591 19.330 - 3.331
Global Peer ELI LILLY AND COMPANY NYSE 245,501.066 39.637 40.296 35.5868 1.153
Global Peer NOVARTIS AG ADR-EACH REPR 1 CHF0.5(REGD) NYSE 225,695.078 27.794 25.094 4.1763 2.079
Global Peer ABBVIE INC NYSE 205,323.075 45.067 35.158 - 4.161
Global Peer MERCK & CO INC NYSE 193,474.705 27.377 34.729 - 3.243
Global Peer ASTRAZENECA SPON ADR EACH REP 0.50 ORD SHS NASDAQ 178,643.942 55.465 47.067 11.3959 2.013
Global Peer NOVO NORDISK A/S ADR-EACH CNV INTO 1 CLASS B DKK1 NYSE 165,060.787 25.615 24.553 17.8558 1.445
Global Peer BRISTOL-MYERS SQUIBB CO NYSE 154,014.444 - - 4.1843 2.681
Global Peer SANOFI SPON ADR ECH REP 0.5 ORD SHS NASDAQ 130,125.050 9.270 18.790 1.7352 2.597
Other Global Peers GLAXOSMITHKLINE ADR EACH CNV INTO 2 ORD GBP0.25 (NYSE), WUXI APPTEC (HKEx), TAKEDA PHARMACEUTICAL CO LTD SPON ADS EACH REP 0.5 ORD SHS (NYSE), ROYALTY PHARMA PLC (NASDAQ), HANSOH PHARMA (HKEx), VIATRIS INC (NASDAQ), CANSINOBIO-B (HKEx), INNOVENT BIO (HKEx), REPLIGEN CORP (NASDAQ), CUREVAC NV (NASDAQ), SINOPHARM (HKEx), BIOHAVEN PHARMACEUTICAL HLDG CO LTD (NYSE), HUTCHMED (HKEx), ORGANON & CO (NYSE), HUTCHMED (CHINA) LIMITED SPON ADS EACH REPR 5 ORD SHS (NASDAQ), ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS (NASDAQ), JUNSHI BIO (HKEx), REMEGEN-B (HKEx), LEGEND BIOTECH CORP SPON ADS EACH REP 2 ORD SHS (NASDAQ), HYGEIA HEALTH (HKEx), I MAB SPON ADS EACH REP 2.3 ORD SHS (NASDAQ), SH PHARMA (HKEx), AKESO-B (HKEx), CMS (HKEx), APELLIS PHARMACEUTICALS INC (NASDAQ), INNOCARE-B (HKEx), REATA PHARMACEUTICALS INC (NASDAQ), BAIYUNSHAN PH (HKEx), IMMUNITYBIO INC (NASDAQ), ALLAKOS INC (NASDAQ), SPRINGWORKS THERAPEUTICS INC (NASDAQ), GRIFOLS SA SPON ADR EA REPR 1 ORD EUR0.10 (NASDAQ), CEREVEL THERAPEUTICS HLDGS INC (NASDAQ), CHINARES PHARMA (HKEx), EMERGENT BIOSOLUTIONS INC (NYSE), KARUNA THERAPEUTICS INC (NASDAQ), TURNING POINT THERAPEUTICS INC (NASDAQ), SIMCERE PHARMA (HKEx), TRAD CHI MED (HKEx), CHINAGRANDPHARM (HKEx), NEKTAR THERAPEUTICS (NASDAQ), DICERNA PHARMACEUTICALS INC. (NASDAQ), OPKO HEALTH INC (NASDAQ), ATAI LIFE SCIENCES NV (NASDAQ), EVEREST MED-B (HKEx), CSTONE PHARMA-B (HKEx), HENLIUS (HKEx), ERASCA INC (NASDAQ), CARSGEN-B (HKEx), ATEA PHARMACEUTICALS INC (NASDAQ), IGM BIOSCIENCES INC (NASDAQ), SSY GROUP (HKEx), HEPALINK (HKEx), QUANTERIX CORPORATION (NASDAQ), OCUMENSION-B (HKEx), CENTESSA PHARMACEUTICALS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), ADC THERAPEUTICS SA (NYSE), HARMONY BIOSCIENCES HLDGS INC (NASDAQ), AMNEAL PHARMACEUTICALS INC (NYSE), Y-MABS THERAPEUTICS INC (NASDAQ), ZYMEWORKS INC (NYSE), DAY ONE BIOPHARMACEUTICALS INC (NASDAQ), NURIX THERAPEUTICS INC (NASDAQ), BROOKLYN IMMUNO THERAPEUTICS INC (NYSE American), UNITED LAB (HKEx), ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS (NASDAQ), KRYSTAL BIOTECH INC (NASDAQ), ANTENGENE-B (HKEx), GENERATION BIO CO (NASDAQ), REPARE THERAPEUTICS INC (NASDAQ), CONNECT BIOPHARMA HLDGS LTD ADS EACH REP ONE ORD SHARE (NASDAQ), TONGRENTANGCM (HKEx), ARCUTIS BIOTHERAPEUTICS INC (NASDAQ), KRONOS BIO INC (NASDAQ), FORMA THERAPEUTICS HLDGS INC (NASDAQ), Kimia Farma Tbk. (IDX), IMMUNOTECH-B (HKEx), KINIKSA PHARMACEUTICALS LTD (NASDAQ), CULLINAN ONCOLOGY INC (NASDAQ), SCICLONE PHARMA (HKEx), SILVERBACK THERAPEUTICS INC (NASDAQ), MIND MEDICINE (MINDMED) INC (NASDAQ), PETIQ INC (NASDAQ), CKLIFE SCIENCES (HKEx), GH RESEARCH PLC (NASDAQ), PHATHOM PHARMACEUTICALS INC (NASDAQ), PHIBRO ANIMAL HEALTH CORP (NASDAQ), OLEMA PHARMACEUTICALS INC (NASDAQ), KINNATE BIOPHARMA INC (NASDAQ), ICOSAVAX INC (NASDAQ), ESSA PHARMA INC (NASDAQ), ARCTURUS THERAPEUTICS HOLDINGS INC (NASDAQ), IDEAYA BIOSCIENCES INC (NASDAQ), OCULAR THERAPEUTIX INC (NASDAQ), KEROS THERAPEUTICS INC (NASDAQ), NRX PHARMACEUTICALS INC (NASDAQ), ANNEXON INC (NASDAQ), SUTRO BIOPHARMA INC (NASDAQ), SHINEWAY PHARM (HKEx), AKERO THERAPEUTICS INC (NASDAQ), POINT BIOPHARMA GLOBAL INC (NASDAQ), CALLIDITAS THERAPEUTICS AB SPON ADS EACH REP 2 ORD SHS (NASDAQ), G1 THERAPEUTICS IN (NASDAQ), TENAYA THERAPEUTICS INC (NASDAQ), ADAGENE INC SPON ADS EACH REP 1.25 ORD SHS (NASDAQ), PRAXIS PRECISION MEDICINES INC (NASDAQ), CRINETICS PHARMACEUTICALS INC (NASDAQ), ALPHA TEKNOVA INC (NASDAQ), ALIGOS THERAPEUTICS INC (NASDAQ), ORIC PHARMACEUTICALS INC (NASDAQ), EVOLUS INC (NASDAQ), TALARIS THERAPEUTICS INC (NASDAQ), GOSSAMER BIO INC (NASDAQ), ZHAOKE OPHTH-B (HKEx), CHINOOK THERAPEUTICS INC (NASDAQ), ACUMEN PHARMACEUTICALS INC (NASDAQ), VERU INC (NASDAQ), VACCITECH PLC ADR EACH REPR 1 ORD SH SPON (NASDAQ), CLENE INC (NASDAQ), PHARVARIS NV (NASDAQ), AC IMMUNE SA (NASDAQ), EVELO BIOSCIENCES INC (NASDAQ), KALVISTA PHARMACEUTICALS INC (NASDAQ), HUA MEDICINE-B (HKEx), NANOBIOTIX S A SPON ADS EACH REP 1 ORD SHS (NASDAQ), TCR2 THERAPEUTICS INC (NASDAQ), SIGA TECHNOLOGIES INC (NASDAQ), Soho Global Health Tbk. (IDX), TARSUS PHARMACEUTICALS INC (NASDAQ), WEREWOLF THERAPEUTICS INC (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), MIRUM PHARMACEUTICALS INC (NASDAQ), RELMADA THERAPEUTICS INC (NASDAQ), BOLT BIOTHERAPEUTICS INC (NASDAQ), ATHENEX INC (NASDAQ), IGBB (Bursa), STARPHARMA HOLDINGS LIMITED (ASX), SPERO THERAPEUTICS INC (NASDAQ), PROVENTION BIO INC (NASDAQ), CODIAK BIOSCIENCES INC (NASDAQ), BIOMEA FUSION INC (NASDAQ), AMRYT PHARMA PLC (NEW) SPON ADS EACH REP 5 ORD SHS (NASDAQ), ALZAMEND NEURO INC (NASDAQ), INOZYME PHARMA INC (NASDAQ), BEYONDSPRING INC (NASDAQ), OYSTER POINT PHARMA INC (NASDAQ), XOMA CORP (NASDAQ), FUSION PHARMACEUTICALS INC (NASDAQ), RACE ONCOLOGY LTD (ASX), PYC THERAPEUTICS LIMITED (ASX), ORCHARD THERAPEUTICS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), GRITSTONE BIO INC (NASDAQ), 89BIO INC (NASDAQ), THERATECHNOLOGIES INC (NASDAQ), ANNOVIS BIO INC (NYSE American), IMPEL NEUROPHARMA INC (NASDAQ), AFT PHARMACEUTICALS LTD (ASX), DAWNRAYS PHARMA (HKEx), GAMIDA CELL LTD (NASDAQ), DURECT CORP (NASDAQ), ANGION BIOMEDICA CORP (NASDAQ), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), TOT BIOPHARM-B (HKEx), PDS BIOTECHNOLOGY CORPORATION (NASDAQ), CLEARSIDE BIOMEDICAL INC (NASDAQ), VERRICA PHARMACEUTICALS INC (NASDAQ), VECTIVBIO HLDG AG (NASDAQ), BSTEAD (Bursa), NAVIDEA BIOPHARMACEUTICALS INC (NYSE American), CITIUS PHARMACEUTICALS INC (NASDAQ), PHARMA (Bursa), SOL GEL TECHNOLOGIES LTD (NASDAQ), OVID THERAPEUTICS INC (NASDAQ), ACHILLES THERAPEUTICS PLC ADS EACH REPR 1 SHARE SPON (NASDAQ), MUSTANG BIO INC (NASDAQ), EYEPOINT PHARMACEUTICALS INC (NASDAQ), FULCRUM THERAPEUTICS INC (NASDAQ), HARROW HEALTH INC (NASDAQ), KALEIDO BIOSCIENCES INC (NASDAQ), FUSEN PHARM (HKEx), 180 LIFE SCIENCES CORP (NASDAQ), IMMUNIC INC (NASDAQ), HOOKIPA PHARMA INC (NASDAQ), NEXIMMUNE INC (NASDAQ), KALA PHARMACEUTICALS INC (NASDAQ), VINCERX PHARMA INC (NASDAQ), 4D PHARMA PLC SPONS ADR EACH REP 8 ORD SHS (NASDAQ), OBSEVA SA (NASDAQ), OSMOTICA PHARMACEUTICALS PLC (NASDAQ), CHECKPOINT THERAPEUTICS INC (NASDAQ), TFF PHARMACEUTICALS INC (NASDAQ), RENEO PHARMACEUTICALS INC (NASDAQ), XERIS PHARMACEUTICALS INC (NASDAQ), GALERA THERAPEUTICS INC (NASDAQ), TYME TECHNOLOGIES INC (NASDAQ), ONCTERNAL THERAPEUTICS INC (NASDAQ), LANNETT CO INC (NYSE), IP (SET), CH BIOTECH SER (HKEx), TRICIDA INC (NASDAQ), PHASEBIO PHARMACEUTICALS INC (NASDAQ), ANEBULO PHARMACEUTICALS INC (NASDAQ), MILESTONE PHARMACEUTICALS INC (NASDAQ), AYALA PHARMACEUTICALS INC (NASDAQ), ORPHAZYME A/S SPON ADS REP 1 ORD SHS (NASDAQ), SATSUMA PHARMACEUTICALS INC (NASDAQ), ADAMIS PHARMACEUTICALS CORPORATION (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), QILIAN INTERNATIONAL HLDG GROUP LTD (NASDAQ), POLYPID LTD (NASDAQ), SCPHARMACEUTICALS INC (NASDAQ), IMARA INC (NASDAQ), LANTERN PHARMA INC (NASDAQ), VYNE THERAPEUTICS INC (NASDAQ), ETON PHARMACEUTICALS INC (NASDAQ), GENPREX INC (NASDAQ), LOGICBIO THERAPEUTICS INC (NASDAQ), ZHONGZHIPHARM (HKEx), CYCLERION THERAPEUTICS INC (NASDAQ), ODONATE THERAPEUTICS INC (NASDAQ), NOXOPHARM LTD (ASX), ENTERA BIO LTD (NASDAQ), NOVAN INC (NASDAQ), NEUBASE THERAPEUTICS INC (NASDAQ), RECCE PHARMACEUTICALS LTD (ASX), LIQUIDIA CORPORATION (NASDAQ), AQUESTIVE THERAPEUTICS INC (NASDAQ), REGENCELL BIOSCIENCE HLDGS LTD (NASDAQ), GALECTO INC (NASDAQ), Merck Tbk. (IDX), PROPHASE LABS INC (NASDAQ), EYENOVIA INC (NASDAQ), F-STAR THERAPEUTICS INC (NASDAQ), MEDIWOUND LTD (NASDAQ), AYTU BIOPHARMA INC (NASDAQ), YUMANITY THERAPEUTICS INC (NASDAQ), CRESO PHARMA LTD (ASX), TEMPEST THERAPEUTICS INC (NASDAQ), AERPIO PHARMACEUTICALS INC (NASDAQ), PURPLE BIOTECH LTD SPON ADS EACH REP 10 ORD SHS (NASDAQ), ELEDON PHARMACEUTICALS INC (NASDAQ), PROTARA THERAPEUTICS INC (NASDAQ), NEW RAY MEDIC (HKEx), AILERON THERAPEUTICS INC (NASDAQ), APREA THERAPEUTICS INC (NASDAQ), MOLECULIN BIOTECH INC (NASDAQ), CHARMACY PHAR (HKEx), APTORUM GROUP LIMITED (NASDAQ), GRAYBUG VISION INC (NASDAQ), LYRA THERAPEUTICS INC (NASDAQ), KOTRA (Bursa), CORVUS PHARMACEUTICALS INC (NASDAQ), NC HEALTHCARE (HKEx), DARE BIOSCIENCE INC (NASDAQ), AKARI THERAPEUTICS PLC SPON ADR EACH REPR 100 ORD (NASDAQ), ADDEX THERAPEUTICS LIMITED SPON ADS EACH REP 6 ORD SHS (NASDAQ), Phapros Tbk. (IDX), PAK FAH YEOW (HKEx), ALLENA PHARMACEUTICALS INC (NASDAQ), OCUPHIRE PHARMA INC (NASDAQ), EDESA BIOTECH INC (NASDAQ), NOVA (Bursa), MODERN CHI MED (HKEx), BIOHLDG (Bursa), INHIBIKASE THERAPEUTICS INC (NASDAQ), INVION LTD (ASX), BRICKELL BIOTECH INC (NASDAQ), MANNATECH INC (NASDAQ), UNIVERSE PHARMACEUTICALS INC (NASDAQ), ARIDIS PHARMACEUTICAL INC (NASDAQ), EXOPHARM LTD (ASX), ASSERTIO HOLDINGS INC (NASDAQ), NEP INTERLONG (HKEx), ACURX PHARMACEUTICALS INC (NASDAQ), BAUDAX BIO INC (NASDAQ), SYNAPTOGENIX INC (NASDAQ), AGEX THERAPEUTICS INC (NYSE American), WAI YUEN TONG (HKEx), MEDLAB CLINICAL LIMITED (ASX), VIRIOS THERAPEUTICS INC (NASDAQ), ADIAL PHARMACEUTICALS INC (NASDAQ), PALLA PHARMA LTD (ASX), TBG DIAGNOSTICS LTD (ASX), TELIGENT INC NEW (NASDAQ), CNS PHARMACEUTICALS INC (NASDAQ), TREVI THERAPEUTICS INC (NASDAQ), BIONDVAX PHARMACEUTICALS SPON ADS REP 40 ORD SHS (NASDAQ), PURAPHARM (HKEx), TIMBER PHARMACEUTICALS INC (NYSE American), EXTRAWELL PHAR (HKEx), SANAI HEALTH GP (HKEx), ACER THERAPEUTICS INC (NASDAQ), PANBELA THERAPEUTICS INC (NASDAQ), PHARMAXIS (ASX), HOTH THERAPEUTICS INC (NASDAQ), REVIVA PHARMACEUTICALS HOLDINGS INC (NASDAQ), JCT (SET), VALLON PHARMACEUTICALS INC (NASDAQ), SUNZEN (Bursa), AVENUE THERAPEUTICS INC (NASDAQ), NLS PHARMACEUTICS LTD (NASDAQ), PETROS PHARMACEUTICALS INC (NASDAQ), ONCOSIL MEDICAL LIMITED (ASX), PAINREFORM LTD (NASDAQ), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), IMMURON LIMITED (ASX), TALI DIGITAL LIMITED (ASX), ACRUX (ASX), VIRPAX PHARMA INC (NASDAQ), TITAN PHARMACEUTICAL INC (NASDAQ), SINOLIFE UTD (HKEx), CHINA SXT PHARMACEUTICALS INC (NASDAQ), SUDA PHARMACEUTICALS LTD (ASX), ISLAND PHARMACEUTICALS LTD (ASX), PASHUN INT'L (HKEx), FIJI KAVA LTD (ASX), FARMAFORCE LTD (ASX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days --0.005
-1.59 %
10 Days --0.010
-3.12 %
20 Days --0.020
-6.06 %
Medium Term Return 3 Months 0.006-0.005
+0.32 %
6 Months 0.006-0.015
-2.77 %
1 Year 0.006-0.270
-45.52 %
Long Term Return 2 Years 0.016+0.110
+63.00 %
3 Years 0.022+0.095
+54.42 %
Annualised Return Annualised --
+15.58 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 0.285 - 0.615 Change From 1 Year Low +0.025 % Change From 1 Year Low (%) +8.77
Change From 1 Year High -0.305 % Change From 1 Year High (%) -49.59
2 Years Range 0.180 - 0.625 Change From 2 Years Low +0.130 % Change From 2 Years Low (%) +72.22
Change From 2 Years High -0.315 % Change From 2 Years High (%) -50.40
5 Years Range 0.160 - 0.625 Change From 5 Years Low +0.150 % Change From 5 Years Low (%) +93.75
Change From 5 Years High -0.315 % Change From 5 Years High (%) -50.40
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

Hyphens Pharma International Limited and its subsidiaries (the "Group") is one of Singapores leading specialty pharmaceutical and consumer healthcare groups leveraging on its diverse footprint in ASEAN countries. The Group has a direct presence in five ASEAN countries, namely, Singapore, Vietnam, Malaysia, Indonesia and the Philippines, supplemented by a marketing and distribution network covering five additional jurisdictions, namely, Hong Kong, Myanmar, Brunei, Cambodia and Oman. Singapore is the Groups regional headquarters, where its strategic planning, finance, regulatory affairs, research and development, legal, business development and logistics operations are based.The Groups core business comprises the following segments: specialty pharma principals, proprietary brands, and medical hypermart and digital. Besides marketing and selling a range of specialty pharmaceutical products in selected ASEAN countries through exclusive distributorship or licensing and supply agreements with brand principals mainly from Europe and the United States, the Group also develops, markets and sells its own proprietary range of dermatological products and health supplement products. In addition, the Group operates a medical hypermart for healthcare professionals, healthcare institutions and retail pharmacies, to supply pharmaceutical products and medical supplies.

IPO Performance

Listing Date 18 May 2018 Full Subscription Rate (x) 17.91
No of Placement Shares (M) 23.79 No of Public Offer Shares (M) 3.00 Public Offer Subscription Rate (x) 151.99
IPO Price (SGD) a 0.260 First Day Close (SGD) a 0.275 First Week Close (SGD) a 0.260
Current vs IPO Price (%) +19.23 First Day Gain (%) +5.77 First Week Gain (%) -
Notes:
  1. Adjusted for the following: 23,790,000 Placement Shares do not include the 2,810,000 Reserved Shares.

Reports Download

Report Type Financial Year Ended Download
Annual Report
Annual Report 2020 Dec 2020 Part 1(8.67 MB)
Annual Report 2019 Dec 2019 Part 1(6.40 MB)
Annual Report 2018 Dec 2018 Part 1(7.14 MB)
IPO Prospectus
IPO Prospectus 2018 May 2018 Part 1(2.57 MB)
Part 2(0.27 MB)

Historical Price Data

Date Open High Low Close Volume VWAP
03 Aug 2021 0.310 0.310 0.305 0.305 110,400 0.3057
02 Aug 2021 0.310 0.310 0.310 0.310 280,300 0.3100
30 Jul 2021 0.315 0.315 0.315 0.315 27,300 0.3150
29 Jul 2021 0.315 0.320 0.315 0.320 58,700 0.3150
28 Jul 2021 0.315 0.315 0.310 0.315 124,400 0.3129
27 Jul 2021 0.315 0.315 0.315 0.315 55,500 0.3150
26 Jul 2021 0.315 0.315 0.315 0.315 29,400 0.3150
23 Jul 2021 0.315 0.315 0.315 0.315 - -
22 Jul 2021 0.315 0.315 0.315 0.315 43,400 0.3150
21 Jul 2021 0.315 0.320 0.315 0.320 54,300 0.3150
19 Jul 2021 0.315 0.320 0.315 0.320 70,000 0.3189
16 Jul 2021 0.320 0.320 0.315 0.320 75,900 0.3190
15 Jul 2021 0.325 0.325 0.320 0.325 84,300 0.3214
14 Jul 2021 0.320 0.330 0.320 0.330 14,300 0.3203
13 Jul 2021 0.315 0.320 0.315 0.320 77,000 0.3194
12 Jul 2021 0.315 0.315 0.315 0.315 28,600 0.3150
09 Jul 2021 0.315 0.320 0.315 0.320 48,100 0.3195
08 Jul 2021 0.320 0.320 0.315 0.315 223,500 0.3177
07 Jul 2021 0.325 0.325 0.320 0.320 160,000 0.3225
06 Jul 2021 0.325 0.330 0.325 0.330 94,200 0.3250
05 Jul 2021 0.325 0.330 0.325 0.330 83,800 0.3287
02 Jul 2021 0.330 0.330 0.325 0.325 390,700 0.3276
Summary
Current 2 Weeks
(21 Jul 2021 to 03 Aug 2021)
0.315 0.320 0.305 0.305 783,700 -
Previous 2 Weeks
(06 Jul 2021 to 19 Jul 2021)
0.325 0.330 0.305 0.320 875,900 -
4 Weeks from
(08 Jun 2021 to 05 Jul 2021)
0.310 0.320 0.305 0.330 17,762,700 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.
We use Cookies. By continuing to use this webite, you will be agreeing to our Privacy Policy, Terms and Conditions and Cookie Policy.